Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder

André Tadić, Stefanie Wagner, Stanislav Gorbulev, Norbert Dahmen, Christoph Hiemke, Dieter F Braus, Klaus Lieb, André Tadić, Stefanie Wagner, Stanislav Gorbulev, Norbert Dahmen, Christoph Hiemke, Dieter F Braus, Klaus Lieb

Abstract

Background: In Major Depressive Disorder (MDD), treatment outcomes with currently available strategies are often disappointing. Therefore, it is sensible to develop new strategies to increase remission rates in acutely depressed patients. Many studies reported that true drug response can be observed within 14 days (early improvement) of antidepressant treatment. The identical time course of symptom amelioration after early improvement in patients treated with antidepressants of all classes or with placebo strongly suggests a common biological mechanism, which is not specific for a particular antidepressant medication. However, the biology underlying early improvement and final treatment response is not understood and there is no established biological marker as yet, which can predict treatment response for the individual patient before initiation or during the course of antidepressant treatment. Peripheral blood markers and executive functions are particularly promising candidates as markers for the onset of action and thus the prediction of final treatment outcome in MDD.

Methods/design: The present paper presents the rationales, objectives and methods of a multi-centre study applying close-meshed repetitive measurements of peripheral blood and neuropsychological parameters in patients with MDD and healthy controls during a study period of eight weeks for the identification of biomarkers for the onset of antidepressants' action in patients with MDD. Peripheral blood parameters and depression severity are assessed in weekly intervals from baseline to week 8, executive performance in bi-weekly intervals. Patients are participating in a randomized controlled multi-level clinical trial, healthy controls are matched according to mean age, sex and general intelligence.

Discussion: This investigation will help to identify a biomarker or a set of biomarkers with decision-making quality in the treatment of MDD in order to increase the currently disappointing remission rates of antidepressant treatment.

Trial registration: ClinicalTrials.gov NCT00974155.

References

    1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess V, Lépine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J, Arbabzadeh-Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M, Domingo-Salvany A, Ferrer M, Joo SS, Martínez-Alonso M, Matschinger H, Mazzi F, Morgan Z, Morosini P, Palacín C, Romera B, Taub N, Vollebergh WA. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica. 2004;109(Suppl. 420):21–27.
    1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA. 2003;289:3095–3105. doi: 10.1001/jama.289.23.3095.
    1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442. doi: 10.1371/journal.pmed.0030442.
    1. Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. Journal of Mental Health Policy Econ. 2006;9:87–98.
    1. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK. The economic burden of depression in the United States: how did it change between 1990 and 2000? Journal of Clinical Psychiatry. 2003;64:1465–1475. doi: 10.4088/JCP.v64n1211.
    1. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine. 2008;358:252–260. doi: 10.1056/NEJMsa065779.
    1. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:45. doi: 10.1371/journal.pmed.0050045.
    1. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303:47–53. doi: 10.1001/jama.2009.1943.
    1. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Current Psychiatry Report. 2007;9:449–459. doi: 10.1007/s11920-007-0061-3.
    1. Quitkin FM, Rabkin JG, Ross D, Stewart JW. Identification of true drug response to antidepressants. Use of pattern analysis. Archives of General Psychiatry. 1984;41:782–786.
    1. Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W. Use of pattern analysis to identify true drug response. A replication. Archives of General Psychiatry. 1987;44:259–264.
    1. DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg) für die Leitliniengruppe Unipolare Depression. S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression-Langfassung. 2009. , . 1. Auflage 2009. DGPPN, ÄZQ, AWMF-Berlin, Düsseldorf 2009. Internet.
    1. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Möller HJ. WFSBP Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. The World Journal of Biological Psychiatry. 2007;8:67–104. doi: 10.1080/15622970701227829.
    1. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision) American Journal of Psychiatry. 2000;157(Suppl. 4):1–45.
    1. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, Fava M. Timing of onset of antidepressant response with fluoxetine treatment. American Journal of Psychiatry. 2000;157:1423–1428. doi: 10.1176/appi.ajp.157.9.1423.
    1. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, Frazer A. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology. 2004;29:566–579. doi: 10.1038/sj.npp.1300341.
    1. Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. Journal of Affective Disorders. 2009;115:439–449. doi: 10.1016/j.jad.2008.10.011.
    1. Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S, Dose T, Wollweber B, Spieler D, Messer T, Lutz R, Kunzel H, Bierner T, Pollmacher T, Pfister H, Nickel T, Sonntag A, Uhr M, Ising M, Holsboer F, Lucae S. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients. Findings from the Munich Antidepressant Response Signature (MARS) project. Journal of Psychiatric Research. 2008;43:215–229. doi: 10.1016/j.jpsychires.2008.05.002.
    1. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. Journal of Clinical Psychopharmacology. 2006;26:56–60. doi: 10.1097/01.jcp.0000195042.62724.76.
    1. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. Journal of Clinical Psychiatry. 2005;66:148–158. doi: 10.4088/JCP.v66n0201.
    1. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Archives of General Psychiatry. 2006;63:1217–1223. doi: 10.1001/archpsyc.63.11.1217.
    1. Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. Journal of Clinical Psychiatry. 2007;68:1195–1205. doi: 10.4088/JCP.v68n0805.
    1. Szegedi A, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. Journal of Clinical Psychiatry. 2003;64:413–420. doi: 10.4088/JCP.v64n0410.
    1. Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement as a predictor of treatment outcome in patients with major depressive disorder: Why the first 2 weeks really matter-evidence from 6,562 patients. Journal of Clinical Psychiatry. 2009;70:344–353. doi: 10.4088/JCP.07m03780.
    1. Tadić A, Helmreich I, Mergl R, Hautzinger M, Henkel V, Hegerl U. Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. Journal of Affective Disorders. 2010;120:86–93.
    1. Leuchter AF, Cook IA, Hunter AM, Korb AS. A new paradigm fort he prediction of antidepressant treatment response. Dialogues in Clinical Neuroscience. 2009;11:435–446.
    1. Mössner R, Mikova O, Koutsilieri E, Saoud M, Ehlis AC, Müller N, Fallgatter AJ, Riederer P. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry. 2007;8:141–174.
    1. Holsboer F. How can we realize the promise of personalized antidepressant medicines? Nature Reviews Neuroscience. 2008;9:638–646. doi: 10.1038/nrn2453.
    1. Domenici E, Wille' DR, Tozzi F, Prokopenko I, Miller S, McKeown S, Brittain C, Rujescu D, Giegling I, Turck CW, Holsboer F, Bullmore ET, Middleton F, Merlo-Pich E, Alexander RC, Muglia P. Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections. PLoS ONE. 2010;5:e9166. doi: 10.1371/journal.pone.0009166.
    1. Beblo T, Herrmann M. Neuropsychologische Defizite bei depressiven Störungen. Fortschritt Neurologie Psychiatrie. 2000;68:1–11. doi: 10.1055/s-2000-11640.
    1. Beblo T. In: Neuropsychologie affektiver Störungen. Lautenbacher S, Gauggel S (Hrsg.), editor. Neuropsychologie psychischer Störungen. Heidelberg: Springer Verlag; 2004.
    1. Fossati P, Ergis AM, Allilaire JF. Executive functioning in unipolar depression: a review. Encephalopathy. 2005;28:97–107.
    1. Sobin C, Sackeim HA. Psychomotor symptoms of depression. American Journal of Psychiatry. 1997;154:4–17.
    1. Christensen H, Griffiths K, Mackinnon A, Jacomb P. A quantitative review of cognitive deficits in depression and Alzheimer-type dementia. Journal of the International Neuropsychological Society. 1997;3:631–651.
    1. Veiel HO. A preliminary profile of neuropsychological deficits associated with major depression. Journal of Clinical and Experimenal Neuropsychology. 1997;19:587–603. doi: 10.1080/01688639708403745.
    1. Savard RJ, Rey AC, Post RM. Halstead-Reitan Category Test in bipolar and unipolar affective disorders. Relationship to age and phase of illness. Journal of Nervous and Mental Disease. 1980;168:297–304. doi: 10.1097/00005053-198005000-00010.
    1. Beblo T, Baumann B, Bogerts B, Wallesch C, Herrmann M. Neuropsychological Correlates of Major Depression: A Short-term Follow-up. Cognitive Neuropsychiatry. 1999;4:333–341. doi: 10.1080/135468099395864.
    1. Potter GC, Kittinger JD, Wagner HR, Steffens DC, Krishnan RR. Prefrontal neuropsychological predictors of treatment remission in late life depression. Neuropsychopharmacology. 2004;29:2266–2271. doi: 10.1038/sj.npp.1300551.
    1. De Groth MH, Nolen WA, Huijsman AM, Bouvy PF. Lateralized neuropsychological functioning in depressive patients before and after drug therapy. Biological Psychiatry. 1996;40:1282–1287. doi: 10.1016/0006-3223(95)00654-0.
    1. Paelecke-Habermann Y, Pohl J, Leplow B. Attention and executive functions in remitted major depression patients. Journal of Affective Disorders. 2005;89:125–135. doi: 10.1016/j.jad.2005.09.006.
    1. Weiland-Fiedler P, Erickson K, Waldeck T, Luckenbaugh DA, Pike D, Bonne O, Charney DS, Neumeister A. Evidence for continuing neuropsychological impairments in depression. Journal of Affective Disorders. 2004;82:253–258. doi: 10.1016/j.jad.2003.10.009.
    1. Nakano Y, Baba H, Maeshima H, Kitajima A, Sakai Y, Baba K, Suzuki T, Mimura M, Arai H. Executive dysfunction in medicated, remitted state of major depression. Journal of Affective Disorders. 2008;111:46–51. doi: 10.1016/j.jad.2008.01.027.
    1. Neu P, Bajbouj M, Schilling A, Godemann F, Berman RM, Schlattmann P. Cognitive function over the treatment course of depression in middle-aged patients: correlation with brain MRI signal hyper intensities. Journal of Psychiatric Research. 2005;39:129–135. doi: 10.1016/j.jpsychires.2004.06.004.
    1. Paradiso S, Lamberty GJ, Garvey MJ, Robinson RG. Cognitive impairment in the euthymic phase of chronic unipolar depression. Journal of Nervous and Mental Disease. 1997;185:748–754. doi: 10.1097/00005053-199712000-00005.
    1. Wong JL, Wetterneck C, Klein A. Effects of depressed mood on verbal memory performance versus self-reports of cognitive difficulties. International Journal of Rehabilitation and Health. 2000;5:85–97. doi: 10.1023/A:1012902121486.
    1. Gorlyn M, Keilp JG, Grunebaum MF, Taylor BP, Oquendo MA, Bruder GE, Stewart JW, Zalsman G, Mann JJ. Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. Journal of Neural Transmission. 2008;115:1213–1219. doi: 10.1007/s00702-008-0084-x.
    1. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA. Regional metabolic effects of Fluoxetine in Major Depression: Serial changes and relationship to clinical response. Biological Psychiatry. 2000;48:830–843. doi: 10.1016/S0006-3223(00)01036-2.
    1. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. British Medical Bulletin. 2003;65:193–207. doi: 10.1093/bmb/65.1.193.
    1. Tadić A, Gorbulev S, Dahmen N, Hiemke C, Braus DF, Röschke J, van Calker D, Wachtlin D, Kronfeld K, Gorbauch T, Seibert-Grafe M, Lieb K. EMC Study Group. Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder-the EMC trial. Trials. 2010;11:21.
    1. Wittchen HU, Weigel A, Pfister H. DIA-X-Diagnostisches Expertensystem. Frankfurt: Swets Test Services; 1996.
    1. Shehaan DV, Lecrubier Y. M.I.N.I. International Neuropsychiatric Interview. USA Tampa; 1998.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4. American Psychiatric Press: Washington DC; 2004.
    1. Dilling H, Mombour W, Schmidt MH. International Classification of Mental and Behavioral Disorders. ICD-10 chapter V. Huber: Bern, Switzerland; 2010.
    1. Wittchen HU, Zaudig M, Fydrich T. SKID-I/-II: Strukturiertes klinisches Interview für DSM-IV. Hogrefe: Göttingen; 1996.
    1. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, Psychiatry. 1960;23:56–62. doi: 10.1136/jnnp.23.1.56.
    1. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi HM. The inventory of Depressive Symptomatology (IDS) Psychological Medicine. 1986;26:477–486. doi: 10.1017/S0033291700035558.
    1. Bullinger M, Kirchberger I. Fragebogen zum Gesundheitszustand - SF 12. Göttingen: Hogrefe Verlag; 1998.
    1. Lehrl S. Erlangen: Perimed Fachbuch Verlagsgesellschaft mbH; 1969. Mehrfachwahl-Wortschatz-Intelligenztest (MWT-B)
    1. Aschenbrenner S, Tucha O, Lange KW. RWT. Regensburger Wortflüssigkeits-Test. Göttingen: Hogrefe; 2000.
    1. Reitan RM. Trail Making Test - Manual for Administration and Scoring. Tucson: Reitan Neuropsychology Laboratory; 1979.
    1. Werheid K, Hoppe C, Thöne A, Müller U, Müngersdorf M, von Cramon DY. The Adaptive Digit Ordering Test clinical application, reliability and validity of a verbal working memory test. Archives of Clinical Neuropsychology. 2002;17:547–565.
    1. Ruff R. Ruff Figural Fluency Test (RFFT) San Diego: Neuropsychological resources; 1988.
    1. Müller MJ, Dragicevic A. Standardized rater training for the Hamilton Depression Rating Scale (HAMD-17) in psychiatric novices. Journal of Affective Disorders. 2003;77:65–69.
    1. Wagner S, Baskaya Ö, Lieb K, Tadic A. Standardized rater training for the Hamilton Depression Scale (HAMD17) and the Inventory of Depressive Symptoms (IDS30CR) Psychopathology. 2011;44:68–70. doi: 10.1159/000318162.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren